Liver Diseases  >>  odanacatib (MK-0822)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT01512693: Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Completed
1
17
NA
MK-0822, odanacatib
Merck Sharp & Dohme LLC
Hepatic Insufficiency
04/12
04/12

Download Options